The cases presented by us and Riar and colleagues indicate that agents reducing the need for endogenous insulin secretion (ie, metformin and SGLT2i) are associated with improvements in blood glucose levels, whereas agents with beta cell stimulating effects are associated with progressive hyperglycemia, suggesting a potential negative impact on beta cell function (3). This evidence concerns the gene INS and Hyperglycemia.